The clearance of BNP modeled using the NT-proBNP–BNP relationship

Kroll, Martin H.; Srisawasdi, Pornpen

doi:10.1016/j.biosystems.2006.05.004

Cited by 26 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BNP levels are available within 20 to 30 min. Unfortunately no fixed equation reliably enables a conversion from BNP to NTproBNP or vice versa due to the nonlinear ratio of both markers [33]. Changing from one marker to the other is not recommended once a hospital has become familiar with either peptide.…”

Section: Laboratory Assaysmentioning

confidence: 99%

BNP or NTproBNP? A clinician's perspective

Steiner

Guglin

2008

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Laboratory Assaysmentioning

confidence: 99%

BNP or NTproBNP? A clinician's perspective

Steiner

Guglin

2008

International Journal of Cardiology

View full text Add to dashboard Cite

“…This limitation is unlikely to weaken the strength of our data because the lack of adjustment tends to dilute the impact of eGFR group membership on the NT-proBNP levels. Sixth, we did not measure BNP so we could not determine whether BNP was increased to a greater extent than NT-proBNP in eGFR group 1 [24,25,26]. Finally, our study involved only patients with dyspnea and included only 3 patients with an eGFR <30 ml/min per 1.73 m 2 .…”

Section: Discussionmentioning

confidence: 99%

Elevated Levels of N-Terminal Pro-Brain Natriuretic Peptide in Patients with Chronic Dyspnea and Moderate Renal Dysfunction: Decreased Clearance or Increased Cardiac Stress

Wieshammer¹,

Dreyhaupt

Basler

2011

Cardiorenal Med

View full text Add to dashboard Cite

Background/Aims: Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are often increased in patients with impaired renal function. The objective of this study was to investigate whether the increase in NT-proBNP is predominantly due to a reduced renal clearance or an increased cardiac secretion. Methods: A series of 697 outpatients (age: 57.5 ± 16.4 years) referred for evaluation of dyspnea were assigned to 4 groups according to their estimated glomerular filtration rate [eGFR (ml/min per 1.73 m²)]: group 1, eGFR <60 (n = 77); group 2, eGFR ≧60 to <75 (n = 139); group 3, eGFR ≧75 to <90 (n = 191), and group 4, eGFR ≧90 (n = 289). The patients were also grouped into 2 categories based on the presence (n = 176) or absence (n = 521) of heart disease. Results: In patients with heart disease, the adjusted values for NT-proBNP were higher in eGFR group 1 than in eGFR groups 2–4 (p ≤ 0.01). In patients without heart disease, eGFR group 1 membership had no effect on NT-proBNP. Conclusion: A reduced renal clearance does not explain increased NT-proBNP levels in patients with moderate renal impairment and dyspnea. Our data suggest that a moderate reduction in renal function places additional stress on the heart in patients with established cardiac disease.

show abstract

“…This would suggest that this NP may be more affected by renal disease, but results discussed below do not support this conclusion. Nevertheless, these clearance pathways indicate that blood levels of BNP and NT-proBNP will be increased when renal impairment is present [55].…”

Section: Diabetes Mellitusmentioning

confidence: 99%

Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure

Chiong

Jao

2009

Heart Fail Rev

View full text Add to dashboard Cite

The B-type natriuretic peptide (BNP) and the amino-terminal fragment of proBNP (NT-proBNP) are increased in heart failure in proportion to severity of symptoms, degree of left ventricular dysfunction, and elevation of cardiac filling pressures. These natriuretic peptides (NPs) are increasingly used for diagnostic and prognostic purposes in acute heart failure. While NP levels on admission provide independent prognostic information, serial determinations during hospitalization and at discharge better reflect adequacy of treatment and prognosis. The addition of BNP and NT-proBNP to usual clinical decision making enhances detection of high-risk patients who need aggressive follow-up and adjustment of treatment.

show abstract

The clearance of BNP modeled using the NT-proBNP–BNP relationship

Cited by 26 publications

References 19 publications

BNP or NTproBNP? A clinician's perspective

BNP or NTproBNP? A clinician's perspective

Elevated Levels of N-Terminal Pro-Brain Natriuretic Peptide in Patients with Chronic Dyspnea and Moderate Renal Dysfunction: Decreased Clearance or Increased Cardiac Stress

Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure

Contact Info

Product

Resources

About